--- title: 'Director / Senior Director, Market Access & Reimbursement at DELFI Diagnostics, Inc.' canonical: 'https://feeny.ai/job/director-senior-director-market-access-reimbursement-delfi-diagnostics-inc-n4z44ygzc0e5' type: 'job' last_seen: '2026-09-12' --- # Director / Senior Director, Market Access & Reimbursement at DELFI Diagnostics, Inc. - **Company:** DELFI Diagnostics, Inc. - **Location:** Remote - **Employment:** full-time - **Work type:** remote - **Posted:** 2026-08-21 - **Last confirmed live:** 2026-09-12 - **Apply:** https://jobs.lever.co/delfidiagnostics/81b116ba-5613-4119-9929-03fddf137493 ## Job description ## About Us DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. In our passionate pursuit to radically improve health outcomes, we serve humanity when we: Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction. Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey. DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto CA or Baltimore MD offices ## About the Role As DELFI's dedicated Market Access & Reimbursement leader, you will own and build the U.S. access strategy for DELFI's product lines end to end. You will translate DELFI's clinical and health-economic evidence into coding, coverage, and payment strategy that put our early cancer detection products into patient care. This is a hands-on, player-coach role in which you will set strategy and execute it by prioritizing your engagements across working directly with CMS/Medicare, and/or  MACs, and priority regional, integrated, and federal payers. Deep, current CMS/Medicare expertise is the center of gravity for this role. Over time, you will build out the function and the team beneath it. This role operates within DELFI’s compliance framework separating non-promotional scientific exchange from commercial/reimbursement activity; external stakeholder engagement is coordinated with Legal/Compliance. ## What You'll Do - Own and execute DELFI's U.S. market access and reimbursement strategy across product lines, from coding and coverage through payment. - Serve as DELFI's subject-matter expert on CMS/Medicare, including Medicare Administrative Contractors, LCD/NCD processes, MolDX, and the ADLT, gapfill, and crosswalk pricing pathways relevant to novel diagnostics. - Develop and drive coverage strategies with priority payers, including Medicare, regional and integrated payers, and the VA. - Build formal strategic reimbursement plans for new product launches, including evaluation of coding, coverage, and payment options and innovative alternative payment models. - Partner cross-functionally with Medical Affairs, Clinical, Commercial, Regulatory, and Health Economics to align evidence generation with payer requirements and minimize utilization-management restrictions. - Partner with Legal/Compliance to ensure all engagement with payers, professional societies and KOLs complies with applicable law and industry codes, maintaining a clear distinction between non-promotional scientific exchange and commercial/reimbursement activity. - Identify health-economic evidence gaps and translate payer evidence needs into cross-functional study and dossier requirements. - Engage external stakeholders, including payers, health technology assessment bodies, professional societies, and KOLs, to shape favorable coverage policy in coordination with Commercial leadership on downstream adoption and utilization. - Establish the foundational tools, processes, and consultant and advisor network for a scalable market access function, and build the team as the function grows. ## What You'll Bring Required - Bachelor's degree with 12+ years (Director) or 15+ years (Senior Director), or Master's or advanced degree with 10+ or 12+ years of market access and reimbursement experience in diagnostics, medical devices, or pharma. Level will be set at offer based on depth of experience. - Deep, current expertise in CMS/Medicare, including coverage and payment pathways, Medicare Administrative Contractors, LCD/NCD processes, MolDX, and diagnostic-specific pricing mechanisms such as ADLT, gapfill, and crosswalk. - Demonstrated track record securing coverage and payment with CMS and U.S. commercial payers, ideally including regional, integrated, and VA or federal payers. - Expertise in coding classification systems (CPT, HCPCS, ICD-10) and payer policies governing billing and compliance. - Proven ability to build strategy and execute hands-on as a sole functional owner, with the resourcefulness to operate without a team initially. - Excellent communication, presentation, and influencing skills, with a demonstrated ability to reconcile multiple stakeholder views and negotiate matters of significance with senior internal and external leaders. ## Preferred - Experience in molecular diagnostics, genomics, or multi-marker 'omic assays, or in early cancer detection. - Experience building or scaling a market access function from an early stage. - Direct experience with health technology assessment bodies and professional-society guideline strategy. - An advanced degree in public health, public policy, health economics, political science, or business. We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status. This position is not eligible for agency partnership. Resumes and outreach from staffing representatives will be declined. ## About DELFI Diagnostics, Inc. ## Company Overview - **One-liner**: DELFI Diagnostics is a precision oncology company that uses AI and whole-genome sequencing to analyze DNA fragmentation patterns in blood for early cancer detection. - **Entity Type**: Private (Late-Stage) - **Headquarters**: Palo Alto, California, USA - **Founded**: 2019 - **Founders**: Victor Velculescu, MD, PhD (and colleagues at Johns Hopkins University) ## Core Business - Primary industry: Precision Oncology / Liquid Biopsy / Healthcare Diagnostics - Target customers: B2B (Health systems, primary care providers, pulmonologists, lung screening programs) and B2B for research (Pharmaceutical companies) - Mission: "Make cancer less deadly through widely accessible early detection" ## Products & Services - **[FirstLook™ Lung](https://delfidiagnostics.com/)**: A blood-based, AI-powered laboratory-developed test (LDT) for lung cancer screening. Designed for adults eligible under USPSTF guidelines, it uses whole-genome sequencing and machine learning to analyze cell-free DNA fragmentation patterns. It boasts a 99.8% Negative Predictive Value and is intended to be a noninvasive first step before low-dose CT (LDCT) scans. Became commercially available in October 2023. - **[DELFI-TF Treatment Monitoring](https://delfidiagnostics.com/)**: A research service for pharmaceutical companies conducting Phase 1-2 clinical trials. It provides non-invasive, real-time treatment response assessment using cell-free DNA fragmentomes, offering short turnaround times and a low-cost solution. ## Market Standing - **Valuation**: Not publicly disclosed - **Key Metric**: Total Funding of **over $325 million** - **Notable Investors/Partners**: DFJ Growth, Eli Lilly and Company, Merck Global Health Innovation Fund (equity investment announced June 2024), OrbiMed, Point72, T. Rowe Price. - **Growth Signals**: - The FirstLook Lung test is commercially available, marking a major milestone from R&D to clinical deployment. - Completed three major clinical trials (L101 validation study, CASCADE-LUNG/L201 prospective cohort study, L301/FIRSTLUNG randomized controlled trial). - Has a strong intellectual property foundation, with its core technology first published in *Nature* in 2019. - Strategic equity investment from Merck (2024) signals pharma validation and potential for partnership. ## Competitive Advantages - **Proprietary Fragmentomics Platform**: Their AI-driven computational platform analyzes genome-wide patterns of cell-free DNA fragmentation, capturing signals that conventional mutation-based liquid biopsies often miss. This provides a broader, more sensitive view of cancer biology. - **Strong Clinical Validation**: The technology is backed by peer-reviewed publications in top journals (*Nature*, *Cancer Discovery*) and multiple registered clinical trials (NCT04825834, NCT05306288, NCT06145750). - **High Clinical Utility**: The test's 99.8% Negative Predictive Value provides high confidence to rule out lung cancer, which is a powerful tool for clinicians managing screening decisions. - **Focus on Accessibility**: Designed for large-scale health system deployment with EHR integration, provider support, and a low-cost structure to make screening widely available. ## Strategic Focus - **Market Expansion**: Driving commercial adoption of FirstLook Lung within health systems, primary care, and lung screening programs across the US. - **Clinical Evidence Generation**: Continuing to generate robust clinical data through trials like CASCADE-LUNG to further validate the technology's performance and clinical utility. - **Pharma Partnerships**: Expanding the DELFI-TF treatment monitoring service to partner with more pharmaceutical companies for drug development. - **Product Pipeline**: Likely developing additional screening tests for other cancer types using the same fragmentomics platform. ## Why Work Here - **High-Impact Mission**: The company is singularly focused on "making cancer less deadly," offering employees a direct role in a potentially transformative technology. - **Culture & Values**: DELFI emphasizes three core values guiding all interactions and decisions. They actively seek to build a diverse, inclusive, and healthy workplace so employees can do their best work. - **Hybrid/Remote Flexibility**: DELFI supports hybrid and remote work options for most positions, with labs and offices in Palo Alto, CA, and Baltimore, MD. Employees receive a one-time $400 home office subsidy. - **Comprehensive Compensation**: Offers a competitive base salary, target bonus plan, and an equity program so everyone has a stake and feels ownership. - **Generous Benefits**: - Non-accrual time off (flexible PTO) and a 5-day winter break. - DELFI pays 100% of the medical premium for employee and family. - 16 weeks of paid parental leave. - 401(k) and annual merit cycle. - **Learning & Growth**: Wide-ranging learning and development programs to help employees continue to develop their skills. - **Team & Leadership**: A dynamic, passionate group of executive leaders, clinical and data scientists, engineers, and commercial team members, led by experienced experts from relevant fields. ## Sources 1. [delfidiagnostics.com](https://delfidiagnostics.com/) 2. [delfidiagnostics.com/about-us/](https://delfidiagnostics.com/about-us/) 3. [delfidiagnostics.com/about-us/careers/](https://delfidiagnostics.com/about-us/careers/) 4. [jobs.lever.co/delfidiagnostics](https://jobs.lever.co/delfidiagnostics) 5. [delfidiagnostics.com/about-us/leadership-team/](https://delfidiagnostics.com/about-us/leadership-team/) ## Other roles at DELFI Diagnostics, Inc. - [Manager Equipment Service Engineering](https://feeny.ai/job/manager-equipment-service-engineering-delfi-diagnostics-inc-palo-alto-ev10x2yvgs6c) — Palo Alto, CA - [Accounting Operations Manager](https://feeny.ai/job/accounting-operations-manager-delfi-diagnostics-inc-palo-alto-2q3fjaratz5w) — Palo Alto, CA - [Sr. Data Scientist, Assay Development](https://feeny.ai/job/sr-data-scientist-assay-development-delfi-diagnostics-inc-palo-alto-e021867zf5tq) — Palo Alto, CA - [Senior Clinical Laboratory Associate / Equipment Engineer (Contract)](https://feeny.ai/job/senior-clinical-laboratory-associate-equipment-engineer-contract-delfi-59t1g1rbhy4a) — Palo Alto, CA - [IVD Documentation Scientist, Manufacturing and Medical Device (Contract)](https://feeny.ai/job/ivd-documentation-scientist-manufacturing-and-medical-device-contract-delfi-zzcfhgh4mdm8) — Palo Alto, CA - [Automation Engineer I/II (Contract)](https://feeny.ai/job/automation-engineer-i-ii-contract-delfi-diagnostics-inc-palo-alto-zfxef259gcph) — Palo Alto, CA - [Senior Director, Clinical Development](https://feeny.ai/job/senior-director-clinical-development-delfi-diagnostics-inc-palo-alto-06vxbzpnzjqq) — Palo Alto, CA - [Senior Staff, Software Engineer](https://feeny.ai/job/senior-staff-software-engineer-delfi-diagnostics-inc-remote-bjpcbxmnjyd2)